Uchio 2018.

Study characteristics
Methods	Design: parallel Duration: 14 weeks Assessment: baseline and post‐intervention Country: Japan
Participants	Pain condition: knee OA Population: adults aged 40‐80 with chronic knee pain due to OA Minimum pain intensity: ≥ 4 on 0‐10 scale Inclusion criteria Outpatients aged 40 to < 80 years were eligible if they had experienced pain for ≥ 14 days/month during the 3‐month period before Visit 1 BPI‐Severity average pain score of ≥ 4 Patients needed to satisfy the ACR criteria for idiopathic knee OA Exclusion criteria Physical and mental health comorbidities Total participants randomised: 354 Age in years (mean): 65.9 Gender: 274/354 were female Pain duration in years (mean, SD): NR
Interventions	Placebo n = 176 Inert Identical appearance to duloxetine Duloxetine 60 mg n = 177 SNRI Fixed dose, forced titration
Outcomes	Pain intensity Sleep Quality of life Mood Physical function Moderate pain relief Substantial pain relief PGIC AEs SAEs Withdrawal
Missing data methods	ITT with LOCF and BOCF
Funding source	Pharmaceutical: Eli Lilly and Company and Shionogi
Conflicts of interest	TT is an employee of and owns stock in Shionogi Co. Ltd. HE, SF, NS, and HT are employees of Eli Lilly Japan K.K. SF and HE own stock in Eli Lilly and Company. YU has been a member of a Board of Directors and Speakers' Bureau and had a consulting role with Eli Lilly Japan K.K.
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomised participants an Interactive Web Response System and stochastic minimisation method
Allocation concealment (selection bias)	Low risk	Participants were allocated using an Interactive Web Response System
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double‐blind, identical capsules for study drugs, matched doses
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Self‐reported outcomes by blinded participants
Incomplete outcome data (attrition bias) All outcomes	Low risk	Low attrition. Missing data were imputed using the LOCF, BOCF, or the modified BOCF. These findings were consistent for all missing data imputation methods. Attrition Total: 31/354 (8.8%) Placebo: 14/176 (8.0%) Duloxetine 60 mg: 17/178 (10.0%)
Selective reporting (reporting bias)	Low risk	Some results for outcomes (BDI, Patient Global Assessment of Illness) reported on clinicaltrials.gov but not in the paper
Other bias	Low risk	No other sources of bias were identified.